214045-82-6

Basic information

• Product Name: 5-CHLOROPYRIDO[4,3-B]PYRAZINE
• Synonyms: 5-CHLOROPYRIDO[4,3-B]PYRAZINE;Pyrido[3,4-b]pyrazine, 5-chloro-;5-Chloropyrido[3,4-b]pyrazine;5-chloropyrido[3;5-Chloropyridino[3,4-b]pyrazine
• CAS NO: 214045-82-6
• Molecular Formula: C7H4ClN3
• Molecular Weight: 165.57976
• Mol File: 214045-82-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 314.2 °C at 760 mmHg
• Flash Point: 173 °C
• Appearance: /
• Density: 1.437 g/cm³
• Vapor Pressure: 0.000872mmHg at 25°C
• Refractive Index: 1.674
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.44±0.30(Predicted)
• CAS DataBase Reference: 5-CHLOROPYRIDO[4,3-B]PYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLOROPYRIDO[4,3-B]PYRAZINE(214045-82-6)
• EPA Substance Registry System: 5-CHLOROPYRIDO[4,3-B]PYRAZINE(214045-82-6)

Safety Data

• Hazardous Substances Data: 214045-82-6(Hazardous Substances Data)

Usage

General Description

5-CHLOROPYRIDO[4,3-B]PYRAZINE is a chemical compound with the molecular formula C7H4ClN3. It is a heterocyclic organic compound that belongs to the pyridines and pyrazines class of chemicals. 5-CHLOROPYRIDO[4,3-B]PYRAZINE is known for its use in the field of pharmaceuticals and agrochemicals, as it has been studied for its potential use as an active ingredient in the development of new drugs and pesticides. It is also used as an intermediate in the synthesis of various other organic compounds. The presence of the chlorine atom in the structure of 5-CHLOROPYRIDO[4,3-B]PYRAZINE gives it unique chemical properties and reactivity, making it valuable for a variety of industrial applications.

InChI:InChI=1/C7H4ClN3/c8-7-6-5(1-2-11-7)9-3-4-10-6/h1-4H

Upstream product

• 39217-08-8 2-chloropyridine-3,4-diamine 
• 131543-46-9 Glyoxal 
• 517-21-5 glyoxal sodium bisulfite 

Relevant articles and documents

Scaffold Hopping-Driven Optimization of 4-(Quinazolin-4-yl)-3,4-dihydroquinoxalin-2(1 H)-ones as Novel Tubulin Inhibitors

Scaffold hopping-driven lead optimizations were performed based on our prior lead 7-methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one (2a) by C-ring expansion and isometric replacement of the A/B-ring, successively, aimed at finding new potential alternative drug candidates with different scaffold(s), high antitumor activity, and other improved properties to replace prior, once promising drug candidates that failed in further studies. Two series of new compounds 7 (a-d) and 13 (a-j) were synthesized and evaluated for antitumor activity, leading to the discovery of three highly potent compounds 13c, 13d, and 13e with different scaffolds. They exhibited similar high antitumor activity with single digital low nanomolar GI50 values (4.6-9.6 nM) in cellular assays, comparable to lead 2a, clinical drug candidate CA-4, and paclitaxel in the same assays. Further biological evaluations identified new active compounds as tubulin polymerization inhibitors targeting the colchicine binding site. Moreover, 13d showed better aqueous solubility than 2a and a similar log P value.

Pyrido[3,4-b]pyrazines. A new application of 2-chloro-3,4-diaminopyridine

5-Chloropyrido[3,4-b]pyrazines were prepared from 1,2-dicarbonyl compounds and 2-chloro-3,4-diaminopyridine. Condensation of unsymmetrical glyoxals provided a mixture of two regiosiomers with 2-substituted pyrido[3,4-b]-pyrazines as the major product. The regiochemistry was unambiguously assigned by 2D-NMR experiments. C-C- and C-N coupling reactions of 5-chloro or 5-oxo intermediates afforded the corresponding C-5 or N-6 substituted derivatives.